Podcasts about prova education

  • 15PODCASTS
  • 574EPISODES
  • 26mAVG DURATION
  • 1WEEKLY EPISODE
  • Apr 2, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about prova education

Latest podcast episodes about prova education

ReachMD CME
Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Preventing Myasthenic Crisis: Early Signs and Critical Interventions

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Ocular to Generalized MG: How and Why the Disease Evolves

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Managing Side Effects in FcRn Therapy: Best Practices for gMG

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 0.75 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/ The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.=

ReachMD CME
Diagnostic Advances in gMG: Effective Tools and Techniques

ReachMD CME

Play Episode Listen Later Apr 2, 2025


CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

ReachMD CME
Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety

ReachMD CME

Play Episode Listen Later Mar 25, 2025


CME credits: 0.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/ When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need! =

ReachMD CME
Advancing Multidisciplinary Care in TGCT: Integrating Systemic Therapies and Surgical Approaches

ReachMD CME

Play Episode Listen Later Feb 28, 2025


CME credits: 0.25 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-multidisciplinary-care-in-tgct-integrating-systemic-therapies-and-surgical-approaches/29871/ In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT. Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.​=

ReachMD CME
Recent Guidelines Updates: Implications to Practice

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.00 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/recent-guidelines-updates-implications-to-practice/26659/ This series of bite-sized episodes will take you on the winding journey that patients with idiopathic multicentric Castleman disease (iMCD) often undergo to achieve an accurate diagnosis. Once the condition is finally identified, even the most astute specialists can find themselves challenged by the treatment, management, and monitoring of these patients. Join Drs. Corey Casper and Sudipto Mukherjee as they explain the ups and downs of this rare disease.

ReachMD CME
The Power of Shared Decision-Making in Obesity Care

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-shared-decision-making-in-obesity-care/29935/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

ReachMD CME
Personalized Obesity Management: A Comprehensive Approach

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/personalized-obesity-management-a-comprehensive-approach/29933/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

ReachMD CME
Pharmacotherapy in Obesity: Current and Emerging Options

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pharmacotherapy-in-obesity-current-and-emerging-options/29932/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

ReachMD CME
Breaking the Bias: Addressing Stigma in Obesity Care

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-bias-addressing-stigma-in-obesity-care/29931/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

ReachMD CME
Diagnosing Obesity: Beyond BMI

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-obesity-beyond-bmi/29930/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

ReachMD CME
The Power of Teamwork: Multidisciplinary Obesity Care

ReachMD CME

Play Episode Listen Later Dec 31, 2024


CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-teamwork-multidisciplinary-obesity-care/29934/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies available for healthcare professionals so they can optimize patient outcomes. Our series of micro learning activities will provide tips and tools for the implementation of key obesity interventions, including nutritional, physical, behavioral, and pharmacological approaches. Partner with your patients and recognize the importance of treating obesity like any other chronic condition.

ReachMD CME
Emerging immunotherapy combination strategies in genitourinary malignancies

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-immunotherapy-combination-strategies-in-genitourinary-malignancies/29201/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

strategy emerging combination uc attendees cme immunotherapy urology rmd rcc genitourinary nccn reachmd cme/ce oncology and hematology global oncology academy pathology and lab medicine prova education pathology and laboratory medicine
ReachMD CME
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-recommendations-into-the-frontline-care-of-a-patient-with-mcrpc-who-is-naive-to-both-docetaxel-and-novel-hormone-therapy/29197/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-genitourinary-malignancies/29202/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

global patients optimizing uc attendees patient care cme urology rmd rcc genitourinary key opinion leaders nccn reachmd cme/ce oncology and hematology global oncology academy pathology and lab medicine prova education pathology and laboratory medicine
ReachMD CME
Emerging targeted therapy combination strategies in genitourinary malignancies

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-targeted-therapy-combination-strategies-in-genitourinary-malignancies/29200/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

strategy emerging combination uc attendees cme urology rmd rcc targeted therapy genitourinary nccn reachmd cme/ce oncology and hematology global oncology academy pathology and lab medicine prova education pathology and laboratory medicine
ReachMD CME
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-second-line-treatment-following-an-immune-checkpoint-inhibitor-in-renal-cell-carcinoma/29199/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-first-line-treatment-with-immunotherapy-and-targeted-therapy-combinations-in-renal-cell-carcinoma/29198/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-frontline-immunotherapy-based-combination-regimens-in-metastatic-urothelial-cancer/29193/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-concordant-care-for-first-line-treatment-of-a-patient-with-metastatic-urothelial-carcinoma/29195/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

ReachMD CME

Play Episode Listen Later Dec 20, 2024


CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-intensification-with-parp-inhibitor-combinations-in-patients-with-metastatic-castration-resistant-prostate-cancer/29196/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

ReachMD CME
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer

ReachMD CME

Play Episode Listen Later Dec 6, 2024


CME credits: 0.25 Valid until: 06-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-weight-of-recurrence-navigating-multidisciplinary-care-planning-in-recurringmetastatic-cervical-cancer/29168/ In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances. =

ReachMD CME
Advances in the Treatment and Management of MASH: More Options, More Decisions

ReachMD CME

Play Episode Listen Later Dec 4, 2024


CME credits: 1.50 Valid until: 04-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-and-management-of-mash-more-options-more-decisions/24277/ Join us for a CME online broadcast replay of a live satellite symposium from ACG 2024, where experts discuss MASLD/MASH, a serious disease that is both chronic and progressive. What's most concerning is that MASLD/MASH will soon be the most common indication for liver transplantation and a major driver of the development of liver cancer. Until recently there was no liver-directed therapy for this disease, and the metabolic benefits of pharmacologic modification of body weight were underappreciated. This activity will also provide practical interactive discussions of cardiometabolic pathophysiologic pathways; early identification and risk stratification; advances in treatment; monitoring for disease progression; and long-term medical management, including the role of incretin agonists.=

ReachMD CME
Don't Forget, There's a Sleepy Patient Behind Those Numbers

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-a-sleepy-patient-behind-those-numbers/29112/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
Don't Forget, There's an Itchy Patient Behind Those Numbers

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/dont-forget-theres-an-itchy-patient-behind-those-numbers/29113/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
Advances in the Treatment of PBC: Part 1

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-1/29114/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
Advances in the Treatment of PBC: Part 2

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-treatment-of-pbc-part-2/29115/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
Initiating Second-Line Therapy: What, When, and Then What?

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/initiating-second-line-therapy-what-when-and-then-what/29111/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
PBC Target Practice: Normalization Is the New Norm

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-target-practice-normalization-is-the-new-norm/29110/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
PBC Is Risky Business

ReachMD CME

Play Episode Listen Later Nov 8, 2024


CME credits: 1.00 Valid until: 08-11-2025 Claim your CME credit at https://reachmd.com/programs/cme/pbc-is-risky-business/29109/ Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the presence of antimitochondrial antibodies. Outcomes largely depend on early recognition of the disease and prompt institution of treatment. First-line treatment consists of ursodeoxycholic acid, but not all patients sufficiently respond to treatment. It is thus important to monitor patients for response to therapy to know when to initiate second-line treatment. The recent approval of PPAR agonists has greatly improved second-line treatment options, as these therapies not only elicited significantly better biochemical responses and normalized bilirubin levels but also improved extrahepatic symptoms including pruritus and fatigue, leading to better quality of life.

ReachMD CME
Diagnostic Challenges of TED: What General Eye Care Providers Need to Know

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-challenges-of-ted-what-general-eye-care-providers-need-to-know/26960/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
The Burden of TED

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-burden-of-ted/26957/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
Underlying Mediators of Immune Dysregulation in TED

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/underlying-mediators-of-immune-dysregulation-in-ted/26958/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
Diagnostic Challenges of TED: What Endocrinologists Need to Know

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-challenges-of-ted-what-endocrinologists-need-to-know/26959/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
ARVO Recap: What's New in TED

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/arvo-recap-whats-new-in-ted/26964/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
Diagnostic Challenges of TED: What Eye Care Specialists Need to Know

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-challenges-of-ted-what-eye-care-specialists-need-to-know/26961/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
TED: Current Treatments, Current Challenges

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/ted-current-treatments-current-challenges/26962/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
The Future of TED

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-future-of-ted/26963/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
TED: Clinical Trials Spotlight

ReachMD CME

Play Episode Listen Later Sep 30, 2024


CME credits: 1.00 Valid until: 30-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/ted-clinical-trials-spotlight/26965/ Thyroid eye disease (TED) is a relatively rare disease that is challenging to diagnose and has limited treatment options. TED may be overlooked by clinicians due to the wide range of clinical manifestations, ranging from dry eye disease to diplopia, proptosis, eyelid retraction, and sight-threatening optic neuropathy. Although TED is often associated with thyroid disorders such as Graves' disease, cases without typical clinical signs or hyperthyroidism are particularly difficult to identify. Additionally, TED is associated with a significant disease burden for patients due to its debilitating symptoms, disfiguring nature, and the inconvenience and adverse effects associated with available treatments. Tune in to this educational series where expert faculty provide multidisciplinary perspectives on best practices for the diagnosis and treatment of TED.

ReachMD CME
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers

ReachMD CME

Play Episode Listen Later Aug 8, 2024


CME credits: 1.00 Valid until: 08-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/enhancing-treatment-strategies-with-molecular-approaches-in-her2-gastrointestinal-cancers/18134/ Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individualize therapeutic planning and sequencing for patients with HER2+ gastric/GEJ cancers and improve response and durability in mCRC with HER2-directed therapies. The symposium also covers the role of genomic profiling in guiding treatment decisions for HER2+ BTC and emphasizes the importance of interprofessional collaboration in managing adverse events associated with HER2-directed therapies in patients with GI cancer. =

ReachMD CME
Expert Approaches to the Diagnosis of Narcolepsy

ReachMD CME

Play Episode Listen Later Jul 31, 2024


CME credits: 0.75 Valid until: 31-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-approaches-to-the-diagnosis-of-narcolepsy/26360/ The 7 episodes in this program will help you understand how to identify early signs and symptoms of narcolepsy to achieve a timely diagnosis and to then effectively manage this condition. Our experts focus on a well-rounded diagnostic and management approach to address not only the physical but also psychosocial aspects of narcolepsy.